Colitis :: Body responds differently to colitis

A new study being published by the American Physiological Society finds that the body responds differently to colitis (inflammation of the colon) based on whether the disease is acute (sharp and brief) or chronic (long-term).

ADHD :: FDA approves first and only stimulant prodrug VYVANSE as a novel ADHD treatment

Shire plc and its collaborative partner New River Pharmaceuticals Inc., announce the U.S. Food and Drug Administration has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of attention deficit hyperactivity disorder. VYVANSE is a prodrug that is therapeutically inactive until metabolized in the body.

ADHD :: FDA approval of Vyvanse as a novel treatment for ADHD

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) and its collaborative partner New River Pharmaceuticals Inc. (NASDAQ: NRPH) announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for VYVANSE (lisdexamfetamine dimesylate, formerly known as NRP104), for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

E Coli :: E. coli bacteria migrating between humans, chimps in Ugandan park

Scientists from the University of Illinois at Champaign-Urbana have found that people employed in chimpanzee-focused research and tourism in a park in western Uganda are exchanging gastrointestinal bacteria — specifically Escherichia coli — with local chimpanzee populations. And some of the E. coli strains migrating to chimps are resistant to antibiotics used by humans in Uganda.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack